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within the ﬁrst 1–2 weeks and are mainly attributable to mul-
tiple organ dysfunction syndrome (MODS). Depending on
patient selection, necrotizing pancreatitis develops in approxi-
mately 10%–20% of patients and the mortality is high, ranging
from 14% to 25% of these patients. Infected pancreatic necro-
sis develops in 30%–40% of patients with necrotizing pancre-
atitis and the incidence of MODS in such patients is high. The
recurrence rate of acute pancreatitis is relatively high: almost
half the patients with acute alcoholic pancreatitis experience a
recurrence. When the gallstones are not treated, the risk of
recurrence in gallstone pancreatitis ranges from 32% to 61%.
After recovering from acute pancreatitis, about one-third to
one-half of acute pancreatitis patients develop functional dis-
orders, such as diabetes mellitus and fatty stool; the incidence
of chronic pancreatitis after acute pancreatitis ranges from 3%
to 13%. Nevertheless, many reports have shown that most
patients who recover from acute pancreatitis regain good gen-
eral health and return to their usual daily routine. Some au-
thors have emphasized that endocrine function disorders are a
common complication after severe acute pancreatitis has been
treated by pancreatic resection.
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Clinical questions
1. What is the incidence of acute pancreatitis? Is it
different for different countries and areas?
2. What are the causes of acute pancreatitis?
3. What are the risk factors for developing acute
pancreatitis?
4. What are the outcomes of acute pancreatitis?
Abstract
Acute pancreatitis is a common disease with an annual inci-
dence of between 5 and 80 people per 100000 of the popula-
tion. The two major etiological factors responsible for acute
pancreatitis are alcohol and cholelithiasis (gallstones). The
proportion of patients with pancreatitis caused by alcohol or
gallstones varies markedly in different countries and regions.
The incidence of acute alcoholic pancreatitis is considered to
be associated with high alcohol consumption. Although the
incidence of alcoholic pancreatitis is much higher in men than
in women, there is no difference in sexes in the risk involved
after adjusting for alcohol intake. Other risk factors include
endoscopic retrograde cholangiopancreatography, surgery,
therapeutic drugs, HIV infection, hyperlipidemia, and biliary
tract anomalies. Idiopathic acute pancreatitis is deﬁned as
acute pancreatitis in which the etiological factor cannot be
speciﬁed. However, several studies have suggested that this
entity includes cases caused by other speciﬁc disorders such as
microlithiasis. Acute pancreatitis is a potentially fatal disease
with an overall mortality of 2.1%–7.8%. The outcome of acute
pancreatitis is determined by two factors that reﬂect the sever-
ity of the illness: organ failure and pancreatic necrosis. About
half of the deaths in patients with acute pancreatitis occur
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Introduction
The Japanese Society for Emergency Abdominal Medi-
cine, the Japanese Society of Hepato-Biliary-Pancreatic
Surgery, and the Japan Pancreas Society have devel-
oped evidence-based clinical practice guidelines for
acute pancreatitis that integrate all available evidence
regarding the epidemiology and clinical management of
acute pancreatitis published between 1960 and 2000.1 In
this article we have added a review of articles published
since 2000, and we describe the epidemiology, etiology,
natural history, and predictors of disease outcome in
acute pancreatitis.
Clinical questions (CQ) 1. What is the incidence of
acute pancreatitis? Is it different for different coun-
tries and areas?
Studies on the incidence of acute pancreatitis show
large regional differences. Although the diagnostic cri-
teria for acute pancreatitis vary for different countries,
regions, and reports, those reports published since 2000
have revealed that the annual incidence rates of acute
pancreatitis range from 5 to 80 per 100000 (Table 1).
Many studies of trends in the incidence of acute pancre-
atitis have suggested that the numbers have been in-
creasing in recent years.8,9
The ﬁrst national survey in Japan was conducted in
1987 by the Research Group for Acute Pancreatitis and
was organized by the Japanese Ministry of Health and
Welfare. The survey targeted patients treated for acute
pancreatitis between 1982 and 1986 at medical institu-
tions selected by a stratiﬁed random sampling method.
According to the survey, the number of acute pancreati-
tis patients in Japan was estimated to be 14500/year
[95% conﬁdence interval (CI): 9500–19500] and the es-
timated incidence of acute pancreatitis was 12.1/100000.
The second national survey estimated that the number of
patients in 1998 was 19500 (95% CI: 17000–22000) and
the incidence was 15.4/100000 (20.5/100000 for men and
10.6/100000 for women). The ratio of men to women was
1.9 to 1 and incidence peaked in the 7th decade of life in
men and in the 8th decade in women (Fig. 1). Although
the two surveys differed in terms of their subjects and
methods of estimation, the incidence of acute pancreati-
tis is considered to be increasing (evidence level; Level
4).10 Epidemiological studies in Japan have encountered
the following problems: the deﬁnition of acute pancreati-
tis in Japan includes acute exacerbations of chronic
pancreatitis and the data are hospital-based and exclude
autopsy cases. Nevertheless, the incidence of acute pan-
creatitis in Japan is generally considered to be below the
average level found in other countries.
Table 2 summarizes the results of the national survey
conducted in 1998. Severe acute pancreatitis accounted
for 10.3% of all acute pancreatitis cases in the ﬁrst
survey and 25.3% in the second survey.11–13 However, it
cannot be concluded from these statistics that the
incidence of severe acute pancreatitis has increased,
because different criteria were used to evaluate the
severity of acute pancreatitis in the two surveys.
CQ2. What are the causes of acute pancreatitis?
The two major etiological factors responsible for acute
pancreatitis are alcohol and cholelithiasis (gallstones).2
The proportions of pancreatitis attributed to alcohol
and gallstones in all cases of acute pancreatitis vary
considerably for different countries and regions (Table
3).3–7,16,17 In Hungary, the incidence of alcoholic pancre-
atitis is two and a half times that of gallstone pancreati-
tis,14  and the high incidence of acute alcoholic
Table 1. Incidence of acute pancreatitis
Incidence
Author (year) Country/region Subjects (per 100000/year)
Banks2 (2002) England, the Netherlands First attack/recurrence 5–10
Scotland, Denmark First attack/recurrence 25–35
USA, Finland First attack/recurrence 70–80
Tinto et al.3 (2002) UK First attack/recurrence 14.5–20.7
Andersson et al.4 (2004) Sweden First attack/recurrence 30
Lankisch et al.5 (2002) Germany First attack/recurrence 19.7
Gislason et al.6 (2004) Norway First attack/recurrence 30.6
First attack 20
Birgisson et al.7 (2002) Iceland First attack 32
Floyd et al.8 (2002) Denmark Men 27.1
Women 37.8
Japan National Survey (1987) Japan First attack/recurrence 12.1
Japan National Survey (1998) Japan First attack/recurrence (Total) 15.4
First attack/recurrence (men) 20.5
First attack/recurrence (women) 10.612 M. Sekimoto et al.: Epidemiology of acute pancreatitis
Table 2. Etiology and incidence of acute pancreatitis in Japan (national survey in 1999)
All cases Severe cases
Men (%) Women (%) Total (%) Men (%) Women (%) Total (%)
Alcohol 466 (42) 42 (7.2) 508 (30) 138 (49) 14 (11) 152 (37)
Cholelithiasis 219 (20) 183 (31) 402 (24) 44 (16) 37 (30) 81 (20)
Abdominal injury 8 (0.7) 3 (0.5) 11 (0.7) 5 (1.8) 0 (0.0) 5 (1.2)
Surgery 25 (2.3) 18 (3.1) 43 (2.6) 4 (1.4) 3 (2.4) 7 (1.7)
ERCP 27 (2.5) 38 (6.5) 65 (3.9) 6 (2.1) 6 (4.8) 12 (2.9)
EST 12 (1.1) 16 (2.7) 28 (1.7) 5 (1.8) 8 (6.4) 13 (3.2)
Exacerbation of chronic 73 (6.6) 22 (3.7) 95 (5.6) 6 (2.1) 2 (1.6) 8 (2.0)
pancreatitis
Pancreatic cancer 7 (0.6) 4 (0.7) 11 (0.7) 3 (1.1) 2 (1.6) 5 (1.2)
Pancreatobiliary maljunction 8 (0.7) 7 (1.2) 15 (0.9) 1 (0.4) 0 (0.0) 1 (0.2)
Pancreas divism 5 (0.5) 3 (0.5) 8 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Autoimmune diseases 0 (0.0) 4 (0.7) 4 (0.2) 0 (0.0) 1 (0.8) 1 (0.2)
Hyperlipidemia 10 (0.9) 10 (1.7) 20 (1.2) 4 (1.4) 3 (2.4) 7 (1.7)
Drugs 10 (0.9) 11 (1.9) 21 (1.2) 4 (1.4) 4 (3.2) 8 (2.0)
Idiopathic 186 (16.9) 196 (33) 392 (23) 51 (18) 38 (30) 89 (22)
TAE/TAI for hepatoma 0 (0.0) 0 (0.0) 0 (0.0) 0 (18) 0 (0.0) 0 (0.0)
Others 42 (3.8) 30 (5.1) 72 (4.3) 12 (4.2) 7 (5.6) 19 (4.7)
Subtotal 1098 (100) 587 (100) 1685 (100) 283 (100) 125 (100) 408 (100)
Blank 0 3 3 0 1 1
Total 1098 (100) 590 1688 283 126 409
ERCP, endoscopic retrograde cholangiopancreatography; EST, endoscopic sphincterotomy; TAE, transcatheter arterial embolization; TAI,
transcatheter arterial infusion
pancreatitis is considered to be associated with high
levels of alcohol consumption.18 In contrast, the inci-
dence of gallstone pancreatitis is much higher than that
of alcoholic pancreatitis in Greece, Italy, and Nor-
way.6,14 In France, Germany, and Korea, the incidence
of acute alcoholic pancreatitis is slightly higher than that
for gallstone pancreatitis,14,16  whereas the opposite is
true in Mexico and Sweden.4,17  According to a 1999
national survey done in Japan (Table 3), the incidence
of acute alcoholic pancreatitis was fairly similar to that
of gallstone pancreatitis (30% vs. 24%). However, the
survey classiﬁed as alcoholic pancreatitis those cases in
which the consumption of only a small amount of alco-
hol was identiﬁed before the onset of symptoms, so the
incidence of alcoholic pancreatitis may have been over-
estimated. Thus, it remains unknown whether alcoholic
pancreatitis or gallstone pancreatitis has a higher inci-
dence in Japan.
Sex is strongly associated with the risk of acute pan-
creatitis: the incidence of alcoholic pancreatitis is higher
in men, and the incidence of gallstone pancreatitis is
higher in women.14,19 A study on acute pancreatitis in
ﬁve European countries revealed that there were many
more cases of alcoholic pancreatitis in men than women
(90% vs. 10%).14 The 1999 survey done in Japan20 also
revealed that in women the incidence of gallstone pan-
Fig. 1. Incidence of acute pancreatitis in Japan
in 1998. Men, shaded bars; women, white bars
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creatitis was higher than that of alcoholic pancreatitis
(31% vs. 7.2%), whereas in men the incidence of acute
alcoholic pancreatitis was twice that of gallstone acute
pancreatitis (42% vs. 20%). A similar tendency was
observed for severe cases (Table 3). However, a Ger-
man study showed that there was no gender difference
in the risk of acute pancreatitis after adjusting for
alcohol intake.21
Tamakoshi et al. conducted a case-control study
to investigate risk factors associated with the onset of
acute pancreatitis.22 Consumption of more than 100g of
alcohol within 24h before the onset was signiﬁcantly
associated with the risk of acute pancreatitis (odds ratio:
4.4, 95% CI: 1.3–15.5). Lower lipid intake was also asso-
ciated with risk of acute pancreatitis; the risk was lower
(odds ratio: 0.49) in the one-third of subjects with the
highest lipid intake than in the one-third with the
lowest lipid intake. Smoking and average sleep duration
were not associated with increased risk of acute
pancreatitis.
CQ3. What are the risk factors for developing acute
pancreatitis?
Alcohol
Alcohol is one of the two major etiological factors re-
sponsible for acute pancreatitis and several studies have
attempted to quantify the risk of acute alcoholic pancre-
atitis. According to a cohort study in Germany done
between 1988 and 1995, the incidence of acute alcoholic
pancreatitis among those with the highest alcohol in-
take (alcohol consumption 60g/day) was 91.5/100000
per year for men and 81.9/100000 per year for women.21
However, even in the highest-risk group, the risk of
acute alcoholic pancreatitis during a 25-year period was
only 2%–3%. These ﬁndings suggest that factors other
than alcohol also contribute to the occurrence of acute
alcoholic pancreatitis.23
Cholelithiasis
Cholelithiasis is another major etiological factor re-
sponsible for acute pancreatitis. According to a study
done in the United States,24 89 (3.4%) of 2583 cholelithi-
asis patients developed pancreatitis during the follow-
up period, and the relative risk (RR) for acute
pancreatitis in the cholelithiasis patients was 14/35 for
men and 12/25 for women. After adjusting for age and
sex, the risk of acute pancreatitis among patients with
gallstones was 6.3 to 14.8 per 1000 patient-years. How-
ever, the risk dramatically decreased after cholecystec-
tomy to 1.9 per 1000 patient-years for men and 2.0 per
1000 patient-years for women. The RR was decreased
to 1/8 in patients who underwent cholecystectomy, and
recurrence developed in only 2 of the 58 patients after
cholecystectomy (Level 2b).24
Diehl et al. investigated clinical factors associated
with the risk of acute biliary pancreatitis. Multivariate
analyses showed that acute pancreatitis was associated
with a stone diameter of less than 5mm (odds ratio,
4.51; P = 0.007) and with mulberry-shaped gallstones
(odds ratio, 2.25; P = 0.04) (Level 2c).25
Endoscopic retrograde cholangiopancreatography/
endoscopic sphincterotomy
Acute pancreatitis is one of the major complications
of endoscopic retrograde cholangiopancreatography
(ERCP). According to reports from the United States
and Europe, the incidence of acute pancreatitis after
diagnostic ERCP ranged from 0.4% to 1.5% (Level
2c).26–28 The incidence of complications resulting from
endoscopic sphincterotomy (EST) and therapeutic
ERCP was found to be higher than that resulting from
diagnostic ERCP (Levels 2b);29,30  the incidence of
acute pancreatitis after EST and therapeutic ERCP
ranged from 1.6% to 5.4%,26,27,29–31  and the incidence
of severe acute pancreatitis ranged from 0.4% to
0.7%.28,32
Table 3. Etiology of acute pancreatitis by country
Alcohol Cholelithiasis Others
Author (year) Country (%) (%) (%)
Gullo et al.14 (2002) Hungary 60.7 24.0 15.3
France 38.5 24.6 36.9
Germany 37.9 34.9 27.2
Greece 6.0 71.4 22.6
Italy 13.2 60.3 26.5
Cavallini et al.15 (2004) Italy 8.5 60 31.5
Andersson et al.4 (2004) Sweden 30 35 35
Gislason6 (2004) Norway 17 47 36
Kim16 (2003) Korea 32.5 26.6 40.9
Suazo-Barahona et al.17 (1998) Mexico 34 43 23
National survey (1998) Japan 30 24 4614 M. Sekimoto et al.: Epidemiology of acute pancreatitis
Masci et al. conducted a meta-analysis of 15 prospec-
tive clinical studies on complications resulting from
ERCP33 and identiﬁed risk factors for post-ERCP acute
pancreatitis. The relative risk of developing post-ERCP
acute pancreatitis for suspected sphincter of Oddi
dysfunction was 4.09 (95% CI: 3.37–4.96; P < 0.001); for
women 2.23 (95% CI: 1.75–2.84, P < 0.001); for patients
with previous pancreatitis 2.46 (95% CI: 1.93–3.12, P <
0.001); for precut sphincterotomy 2.71 (95% CI: 2.02–
3.63, P < 0.001); and for pancreatic injection 2.2 (95%
CI: 1.6–3.01, P < 0.001). The following factors have also
been enumerated as additional risk factors for acute
pancreatitis: absence of cholangiectasis,26  bile duct
diameter of less than 1cm,31,34–36  older patients,26,37
difﬁculty in cannulation,31,38,39  and performance of
pancreatography.26,35,40–42 Maldonado et al. reported that
the combined use of ERCP and Oddi manometry mark-
edly increased the risk of acute pancreatitis.43  The
incidence of pancreatitis in patients who underwent
sphincter of Oddi manometry alone was signiﬁcantly
lower than that in patients who underwent both ma-
nometry and ERCP (9.3% vs. 26.1%, P < 0.026). The
addition of EST to ERCP, however, had no impact on
the risk of post-ERCP acute pancreatitis.43 There were
no consistent ﬁndings regarding the association be-
tween the use of low-osmolar (nonionic) contrast media
and the risk of post-ERCP acute pancreatitis, and the
issue is still being debated (Levels 1b-2b).29,30,44
A few studies have investigated post-ERCP acute
pancreatitis in Japan. In 1979, Nakajima et al. analyzed
complications after therapeutic ERCP in 25 large medi-
cal institutions across Japan.45 In that survey, EST was
performed in 468 patients over a 5-year period; 9 (2%)
of them developed pancreatitis, but none died. Another
nationwide survey targeted 28 large medical institu-
tions46  and revealed that of the 14947 patients who
underwent diagnostic or therapeutic ERCP between
January 1995 and December 1998, 166 (1.1%) devel-
oped complications. Acute pancreatitis occurred in 89
(0.8%) of the patients who underwent diagnostic
ERCP, and the incidence following therapeutic ERCP
was 1.9%. The incidence of severe acute pancreatitis
among the patients who underwent diagnostic ERCP
and therapeutic ERCP was 0.07% and 0.1%, respec-
tively. One patient who underwent therapeutic ERCP
died, and the overall mortality was 0.007%. The mortal-
ity rate among patients who underwent therapeutic
ERCP was 0.02%.
In the 1980s, there was a lawsuit brought in Japan
after a patient treated by ERCP developed acute
pancreatitis and died. In that case, the court decided
that reparation had to be made for the loss. Since then,
physicians involved in endoscopy and endoscopic
treatment in Japan have striven to prevent acute
pancreatitis, and the Japan Gastroenterological Endos-
copy Society has developed guidelines to prevent
complications related to endoscopy and endoscopic
treatment.47
Surgery and medical procedures
The incidence of postoperative pancreatitis is high after
surgery conducted near the pancreas, such as biliary
tract procedures, gastric surgery, splenectomies, and
splenorenal shunts (Level 4).48,49 Before the introduc-
tion of ERCP and laparoscopic cholecystectomy, the
risk of postoperative acute pancreatitis in patients un-
dergoing biliary surgery was reported to be as high as
10%, with a mortality of 30%–80%.50 Z’graggen et al.
compared the incidence of postoperative pancreatitis
after laparoscopic cholecystectomy (LC) and found that
the risk of pancreatitis increased after conversion to an
open cholecystectomy; the incidence of pancreatitis
after completed LC was 0.34%, whereas that after con-
version was 0.96% (P = 0.02).51 It was possible to estab-
lish a biliary origin for the pancreatitis in 4 (12.5%) of
the 32 patients with postoperative pancreatitis, and no
evidence was found for a causative role of intra-
operative cholangiography or trauma to the pancreas
(Level 2c).51
There have been many reports of pancreatitis devel-
oping after cardiovascular surgery52–57  or transplanta-
tion (e.g., pancreas, liver, kidney, heart, or bone
marrow).58–60 Ramsey and Podratz investigated the inci-
dence of postoperative pancreatitis after gynecological
and obstetric surgery and found that it was very low
overall, occurring in only 1 of 17000 surgical procedures
(Level 2c).61
Other reports have shown the occurrence of acute
pancreatitis following extracorporeal shock wave lithot-
ripsy (ESWL) for gallbladder stones (2%),62  follow-
ing transcatheter arterial embolization (TAE, 33%),63
following percutaneous biliary drainage (PBD) (24%
developed postprocedural hyperamylasemia and 10%
developed postoperative acute pancreatitis),64 following
biliary stent insertion (11.5F stent, 3%; 10F stent,
none),65  following intraoperative irradiation (2/98,
2%),66 and following continuous ambulatory peritoneal
dialysis (CAPD) (0.46 per 100 treatment-years).67 How-
ever, it remains unclear whether these procedures in-
crease the risk of acute pancreatitis.68
Drugs
Many studies have suggested associations between the
use of drugs and the risk of acute pancreatitis, but direct
associations have been demonstrated for only a small
number of drugs (Table 4).69–80 The interval between
drug administration and the onset of symptoms differs
depending on the drug. Certain drugs, such as ace-M. Sekimoto et al.: Epidemiology of acute pancreatitis 15
taminophen, can cause pancreatitis after a single dose.
Others, such as azathioprine, 6-mercaptopurine,
metronidazole, aminosalicylates, and sulfonamides,
characteristically can cause pancreatitis within a month
after exposure, while still others, such as pentamidine,
valproic acid, and didanosine, appear to cause injury
weeks or months after exposure, possibly through the
accumulation of a toxic metabolite (Level 4).80
The drugs reported to be associated with the highest
incidence of acute pancreatitis are azathioprine, mer-
captopurine, and didanosine. An early study on the risk
of acute pancreatitis associated with 6-mercaptopurine
reported that 13 (3.3%) of 400 patients with inﬂamma-
tory bowel disease developed acute pancreatitis.81
However, a case-control study of 490000 residents of
Denmark82 showed that the risk of acute pancreatitis in
patients under treatment with azathioprine was only
1/659. In that study, the odds ratio for the risk of acute
pancreatitis within 90 days after azathioprine adminis-
tration was 7.5 (95% CI: 2.6–21.6), and after adjusting
for cholelithiasis, alcohol, inﬂammatory intestinal dis-
eases, and steroids, the odds ratio was 8.4 (95% CI:
2.6–21.6). Although many HIV patients treated with
didanosine develop acute pancreatitis,83–85 the indepen-
dent risk associated with use of the drug is unknown
(See HIV infection, below).
According to a case-control study done in Sweden
over a 4-year period, 462 of the 1.4 million registered
residents aged between 20 and 85 who did not have a
clear etiological factor for their acute pancreatitis were
hospitalized on their ﬁrst attack of acute pancreatitis. A
multivariate analysis revealed that H2 blockers, proton
pump inhibitors, NSAIDs, and antacids were signiﬁ-
cantly associated with the risk of acute pancreatitis, but
the odd ratios were generally low (1.9–2.4).86
Hyperlipidemia
High blood triglyceride levels of more than 1000–
2000mg/dl are said to increase the risk of acute pancre-
atitis.87 Type V hyperlipidemia, as well as types I and IV,
are prominent causes of acute pancreatitis as a result of
marked hyperlipidemia (Level 4).88 Secondary hyper-
lipidemia is caused by alcohol intake, pregnancy, estro-
gen therapy, and diabetes mellitus, all of which are risk
factors for acute pancreatitis. Genetic polymorphism of
lipoprotein lipase and the apolipoprotein C-II defect,
which cause hyperlipidemia, are also suggested to cause
acute pancreatitis (Level 4).89,90  Some recent studies
have suggested an association between the risk of acute
pancreatitis and marked hypertriglyceridemia related
to the administration of protease inhibitors among
patients with HIV infection.91,92  However, other
reports argue that there is no association between the
two.87,93
The risk of acute pancreatitis associated with hyper-
lipidemia has yet to be determined. A large-scale cohort
study showed that hyperlipidemia accounts for 12%–
38% of all cases of acute pancreatitis,94 whereas another
study suggested that it accounts for only 1.3%–3.8%.95
HIV infection
Acute pancreatitis is one of the main complications of
acquired immunodeﬁciency syndrome (4%–22%), and
the risk increases with the progression of HIV infec-
tion.71  The risk of acute pancreatitis in HIV-infected
populations is 35 to 800 times higher than in populations
without infection.83–85 Although HIV-infected patients
may develop pancreatitis for many reasons, drugs are a
common cause of acute pancreatitis. Before the intro-
duction of antiretroviral therapy, the major mechanisms
responsible for the development of acute pancreatitis
among HIV-infected patients were: (1) pancreatic toxic-
ity resulting from drugs used to treat HIV infection and
(2) immunosuppression by the HIV infection itself.87,96,97
Since 1996, when protease inhibitors were released
on the market and came to be widely used in the treat-
ment of HIV infection, HIV-infected patients have had
a higher incidence of medication-associated hypertrigly-
ceridemia, which is often severe and difﬁcult to treat,
and several reports have suggested that hyper-
triglyceridemia may be involved in the onset of acute
pancreatitis.91,92
Bush and Kosmiski investigated whether the release
of protease inhibitors onto the market changed the
incidence of acute hyperlipidemic pancreatitis in HIV-
infected patients.87  Despite the well-established asso-
ciation between protease inhibitors and hyperlipidemia,
there was no signiﬁcant increase in the prevalence of
hyperlipidemic patients in the HIV-infected population:
the incidence of acute pancreatitis attributed to
hypertriglyceridemia (serum neutral fat level
1000mg/dl) was 3.3% before the sale of protease
inhibitors (1990–1995) and 3.7% after they came on the
Table 4. Drugs that have been reported to cause acute
pancreatitis
l-Asparaginase (anticancer drug)
Azathioprine (immunosuppressant)
Didanosine (anti-HIV drug)
Estrogen
Frosemide (diuretic)
Pentamidine (for pneumocystis carinii infection)
6-Mercaptopurine (anticancer drug)
Salicylates (antipyretic drug)
Stibogluconate sodium (antiprotozoal drug)
Sulfonamide (antimicrobial drug)
Sulindac (antipyretic drug)
Vincristine (anticancer drug)
Vinblastine (anticancer drug)16 M. Sekimoto et al.: Epidemiology of acute pancreatitis
market (1996–2001) (P = 0.6). On the other hand, medi-
cation-induced pancreatitis was the most common kind
in HIV-infected patients: the incidence of medication-
induced acute pancreatitis was 46.6% before the release
of protease inhibitors and 50.0% after the release
(P = 0.6).
Idiopathic
After gallstones and alcohol, the third most common
etiology of acute pancreatitis, regardless of country,
region, or case series, is idiopathic. Acute idiopathic
pancreatitis is deﬁned as acute pancreatitis with a
nonspeciﬁed etiological factor, but it includes those
cases caused by other speciﬁc disorders. Two prospec-
tive studies of apparently idiopathic pancreatitis have
found that two-thirds to three-quarters of the cases had
microlithiasis documented by biliary-drainage studies,
follow-up sonograms, and ERCP (Level 2b).98,99 In the
treatment of acute pancreatitis, the diagnosis of acute
idiopathic pancreatitis should be minimized by identify-
ing the etiological factors based on clinical symptoms
and ﬁndings as well as appropriate tests.
Other factors associated with acute pancreatitis
Other factors associated with acute pancreatitis are
inherited conditions,94,96  pregnancy,100–102  trauma,103,104
viral infections (mumps, Coxsackie B, hepatitis B, cy-
tomegalovirus, herpes simplex II, and varicella-zoster),
bacterial infections (Salmonella typhi, Leptospira, and
Legionella), fungal infection (Aspergillus), parasites
(Toxoplasma,  Cryptosporidium,  Ascaris lumbricoides,
and  Mycoplasma105), collagen diseases (including
systemic lupus erythematosus,106–108 rheumatoid arthri-
tis,109  Sjogren’s syndrome,110  and systemic sclero-
sis111–112), hyperparathyroidism,113–116 and end-stage renal
failure.117,118
Many studies have suggested the involvement of local
predisposing anatomic factors in the etiology of acute
pancreatitis. The presence and diameter of a common
channel, pancreatic duct reﬂux, the angle formed be-
tween the common bile duct and the pancreatic duct,
abnormalities of the Vater’s ampulla (edema, hemor-
rhage, and impacted calculi), patent Santorini’s duct,
and the position of conﬂuence with the cystic duct have
all been suggested to be associated with the develop-
ment of acute pancreatitis (Levels 2b–3b).119–122  Pan-
creas divisum, a congenital variant of pancreatic ductal
anatomy that affects 5%–7% of the general population,
has also been suggested to be associated with acute
pancreatitis. Some reports have shown a signiﬁcantly
higher incidence of pancreas divisum among patients
with acute pancreatitis, including recurrent pancreatitis
(Levels 3b–4).123,124 However, another study reported no
difference in any of these parameters between acute
pancreatitis patients and healthy subjects (Level 2b).125
A randomized controlled clinical trial showed that
stenting of the accessory papilla interrupted the cycle of
recurrent attacks of pancreatitis in patients with pan-
creas divisum (Level 1b).126 Associations between acute
pancreatitis and choledochocele (choledochal cyst),127,128
peripapillary diverticulum,129  ectopic pancreas,130  pan-
creatitis caused by duodenal duplication,131 pancreatitis
accompanying Caroli’s disease,132  and pancreatitis
caused by tumors of the pancreas (cancer of the
pancreas,133–135  metastatic pancreatic tumors,136  and
carcinoid tumors137) have also been reported (Level 4).
However, it remains unclear whether the incidence of
acute pancreatitis is higher in these patients than in
healthy subjects.
Acute pancreatitis in childhood is unusual, and the
etiology in children differs from the etiology in
adults. Steinberg and Tenner reviewed 5 studies involv-
ing a total of 223 children with acute pancreatitis80
and reported that trauma is the leading cause of acute
pancreatitis in children, accounting for 21% of the
cases, followed by idiopathic causes (20%), biliary
tract disease (17%), drugs (15%), infections (10%),
congenital anomalies (6%), and miscellaneous causes
(11%).
CQ4. What are the outcomes of acute pancreatitis?
Recurrence of acute pancreatitis
The rate of recurrence of acute pancreatitis is relatively
high, although it depends on etiological factors and in-
terventions in response to those factors. A study of 1376
inpatients with acute pancreatitis (2211 episodes) dur-
ing the 22-year period from 1975 to 1996 at a university
hospital in Sweden revealed that 21% had had a recur-
rence and that two-thirds of them had experienced the
recurrence within 3 months of the ﬁrst attack.4 Accord-
ing to a prospective cohort study on the recurrence of
acute alcoholic pancreatitis,138 46% had a recurrence of
the disease, and 80% of the recurrent episodes devel-
oped within 4 years of the ﬁrst attack. The recurrence
rate did not change over time (Level 1b). Several stud-
ies have reported that the risk of recurrence of gallstone
pancreatitis ranges from 32% to 61% when the gall-
stones are not treated at the initial hospitalization.139–141
On the other hand, another report has shown that idio-
pathic pancreatitis recurred on average in 1 of 31 pa-
tients during the subsequent 3 years (Level 1b).142 Lee et
al. prospectively studied 23 patients who were diag-
nosed with idiopathic acute pancreatitis but had micro-
scopic evidence of biliary sludge, and they found that
the 12 patients who were treated by cholecystectomy or
papillotomy had fewer recurrences than the 11 un-
treated patients (P = 0.01) (Level 1b).99M. Sekimoto et al.: Epidemiology of acute pancreatitis 17
In Japan, a study group on acute pancreatitis
conducted a follow-up survey of 204 patients with
severe acute pancreatitis who survived to discharge
(excluding 27 late deaths) between 1982 and 1987.143
The results of the survey showed that the overall recur-
rence rate for acute pancreatitis over the long term was
37%. Forty-eight percent of the patients received treat-
ment for recurrent acute pancreatitis, as well as for
complications such as diabetes mellitus and pancreatic
pseudocyst, and 56% of those cases required
hospitalization. The recurrence rates differed between
various etiologies. The recurrence rate in patients with
alcoholic pancreatitis was 51%, which was signiﬁcantly
higher than that among those with other etiological
factors (Level 2b).143  Whereas 67% of patients with
alcoholic pancreatitis received medical treatment, only
29% of those with gallstone pancreatitis required
medical treatment. However, the following must be
taken into consideration when interpreting this survey:
(1) the subjects were restricted to severe cases, (2) some
cases with a favorable course may not have been
included in the survey, and (3) some cases of chronic
pancreatitis may have been classiﬁed as recurrent
cases.
Development of chronic pancreatitis
The incidence of chronic pancreatitis after acute pan-
creatitis ranges from 3% to 13% (Levels 2b–4).144,145
Angelini et al. investigated the frequency of residual
ductal lesions in 118 patients who had recovered from
acute pancreatitis. Occlusive pancreatitis was identiﬁed
by ERCP in 7 patients (8.4%) who had recovered from
necrotizing pancreatitis, and calciﬁed pancreatitis was
observed in 3 such patients (3.6%). Both percentages
were higher than they were for those patients who had
recovered from edematous pancreatitis (Level 1b).146 A
nationwide survey on the long-term outcome in severe
pancreatitis patients in Japan revealed that pancreatic
calculi were subsequently identiﬁed in 17% of such pa-
tients (33.5% of the alcoholic pancreatitis patients and
6.5% of the gallstone pancreatitis patients) and gluco-
suria was identiﬁed in 27% (40% of the alcoholic pan-
creatitis patients and 14% of the gallstone pancreatitis
patients) (Level 2b).146 These data suggest that the se-
verity of, and the etiological factors for, pancreatitis are
closely associated with the development of chronic
pancreatitis.
Mortality
Many cases of acute pancreatitis are ﬁrst diagnosed at
autopsy. Reports in the 1980s (Levels 2b–4)147,148 showed
that the diagnosis was made at necropsy in about 30%–
40% of fatal cases of acute pancreatitis. Recent reports
have also shown that the diagnosis of acute pancreatitis
was made at necropsy in 12%–33% of fatal cases.149,150
The case fatality of acute pancreatitis depends on the
diagnostic criteria, as well as on whether autopsied
cases are included.151 Studies published after 1990 have
shown that the case fatality of acute pancreatitis in the
United States and Europe ranges from 2.1% to 7.8%
(Levels 1b–2b) (Table 5).147,149,151 Many studies have sug-
gested that age is the primary risk factor for death
Table 5. Mortality from acute pancreatitis
Mortality
Author Study period Setting/ country All cases Deaths (%)
Andersson et al.4 1975–1985 University hospital, Sweden 4.7
1986–1996 University hospital, Sweden 3.7
Mann et al.149 1988–1992 Northwest Thames region, UK 631 57 9.0
Talamini et al.152 1976–1992 University hospital, Italy 192a 17 8.8
Lowham et al.153 1996–1997 Inﬁrmary, England 105 6 5.7
Mutinga et al.154 1982–1995 Large tertiary care hospital, USA 805 17 2.1
Blum et al.155 1988–1999 Luneburg County, Germany 351 17 4.6
Floyd et al.8 1981–1985 Denmark 480 44 9.2
1986–1990 Denmark 475 40 8.4
1991–1995 Denmark 609 40 6.6
1996–2000 Denmark 786 53 6.7
Lankisch et al.5 1988–1995 Germany 228 16 7.0
Gullo et al.14 1990–1994 Hungary, Germany, France, Italy, Greece 1068 83 7.8
Kim16 1980–1989 Korea 3.0
1990–1994 Korea 4.4
1995–1999 Korea 2.1
Kandasami et al.156 1994–1999 Malaysia 133 7.5
National survey157 1995–1998 Japan 1240 92 7.4
aFirst attack cases only18 M. Sekimoto et al.: Epidemiology of acute pancreatitis
(Level 1b).150,151 A Japanese survey done from 1991 to
1995 showed that the mortality of severe acute pancre-
atitis is greater than 20% in patients over 50 years of age
(Level 1b).158 According to a 1988 nationwide survey
done in Japan,12 acute pancreatitis mortality was 2%
in moderate cases and 30% in severe cases (Level 4).
According to a 1999 nationwide surveillance,20 overall
mortality was 7.4% and 22% in the severe cases in
Japan (Level 4).
There is a debate as to whether the mortality of acute
pancreatitis has been decreasing in recent years. A few
studies have suggested that the in-hospital mortality is
declining. Andersson et al. reported that the hospital
mortality of acute pancreatitis in a university hospital in
Sweden decreased slightly, from 4.7% (1975–1985) to
3.7% (1986–96), and that the average age of the patients
who died markedly increased, from 59.2 to 73.6 years of
age.4 Tinto et al. have also shown a signiﬁcant decline in
the hospital mortality rate for acute pancreatitis be-
tween the periods 1989–1990 and 1999–2000, during
which the age standardized hospital admission rate for
acute pancreatitis increased by 43%.3 We must be care-
ful in interpreting such data, because the level of patient
risk and the patient background may be different be-
tween the study periods.
Mortality among patients with recurrent attacks is
generally lower than among those experiencing their
ﬁrst attack. A study of 737 hospitalized patients with
acute pancreatitis in Bristol, England, revealed that the
overall mortality between 1968 and 1979 was 20%, but it
was 12% in the patients with recurrent pancreatitis
(Level 4).159 Another hospital-based study showed that
the mortality of patients with relapsing attacks (2.5%)
was signiﬁcantly lower than the overall mortality (4.2%)
among acute pancreatitis patients.4 A European study
of acute pancreatitis that selected 1068 patients in
5 countries (Hungary, Germany, Greece, Italy, and
France) also showed signiﬁcantly lower mortality in re-
current pancreatitis than was the overall mortality from
acute pancreatitis (5.9% vs. 7.8%).14,152
Factors associated with prognosis
The prognosis of acute pancreatitis is determined by
two factors that reﬂect the severity of the disease: organ
failure and pancreatic necrosis. Pancreatic necrosis can
be evaluated by dynamic contrast-enhanced computed
tomography (CT) scanning.160,161 According to the deﬁ-
nitions of the 1992 Atlanta Symposium, the criteria for
organ failure include the following parameters: (1)
shock — systolic blood pressure <90mmHg, (2) respira-
tory failure — PaO2  <60mmHg, (3) renal failure —
serum creatinine >2mg/dl after hydration, and (4) gas-
trointestinal bleeding — blood loss >500ml/24h. The
Research Group sponcered by JMHW has established
independent criteria for the assessment of the sever-
ity,162 and the parameters include dyspnea; shock; cen-
tral nervous system disorders; bleeding tendency;
negative base excess; and signs of organ failure, includ-
ing elevation of the blood urea nitrogen level and the
creatinine level.
Timing of death in acute pancreatitis
Many acute pancreatitis patients die within the ﬁrst few
weeks of the onset of the illness. According to reports
published since 2000, about half of the deaths occur
within the ﬁrst 1–2 weeks, and they are mainly the result
of multiple organ dysfunction syndrome (MODS)154,155
(Table 6). In general, late mortality in patients with
severe acute pancreatitis results mainly from complica-
tions caused by infection, particularly by infectious pan-
Table 6. Comparison of mortality and time of death in acute pancreatitis [National Survey Data (Japan) added to data from the
review by Blum et al.]
Overall Proportion of Proportion of
Number of
mortality early deaths (%) late deaths (%)
Author cases n % n % n %
Mann et al.149 631 57 9 18 32a 39 68
Talamini et al.152 192 17 9 14 82b 31 8
Lowham et al.153 105 6 6 6 100a ——
McKay et al.151 NA NA 8 NA 54a —c 46
Mutinga et al.154 805 8 2 8 47b 95 3
Blum et al.155 368 17 5 7 41a 10 59
National Survey 1131 67d 61 9 2 8 a 48 72
(Japan)157 1131 67d 62 7 4 0 b 40 60
aEarly mortality was deﬁned as death within 1 week
bEarly mortality was deﬁned as death within 2 weeks
cNo single piece of data given
dIncludes only the 67 cases in which acute pancreatitis was presumed to be the cause of death among a total of 94 fatal casesM. Sekimoto et al.: Epidemiology of acute pancreatitis 19
creatic necrosis (Levels 2c–4).163–165  Gloor et al. have
argued that early mortality associated with acute
pancreatitis has decreased as a result of modern inten-
sive care treatment.166 In their case series, the overall
mortality rate was 4% and the mortality rate in patients
with necrotizing pancreatitis was 9%. On the other
hand, some argue that many patients with acute pancre-
atitis still die within the ﬁrst 1–2 weeks after admis-
sion.167  In a large study of acute pancreatitis in the
United Kingdom, 35 deaths occurred among 283 pa-
tients with severe acute pancreatitis, and 13 of those
occurred within the ﬁrst week of illness.168  Japanese
surveys deﬁne early mortality as death within 2 weeks of
admission, and the early mortality rate was 52% in the
period 1982–1986; it then markedly decreased to 29% in
1996.169 According to a 1988 survey, shock followed by
severe dehydration was the leading cause of early death,
and the cause of those deaths that occurred after 2
weeks included renal failure, respiratory failure, gas-
trointestinal hemorrhage, sepsis, and shock (Level
2c).12,13 According to a 1999 survey,157 acute pancreatitis
was the direct cause of death in 67 (73%) of 92 cases.
Twenty-seven deaths (40%) occurred within 2 weeks of
onset, and MODS accounted for 85.2% of these. An-
other 40 deaths occurred 2 weeks or more after onset,
and MODS, including sepsis (67.5%) and disseminated
intravascular coagulation syndrome (62.5%), accounted
for as many as 87.5% of those deaths.
Necrotizing pancreatitis
Depending on patient selection, necrotizing pancreatitis
develops in approximately 10%–20% of acute pancre-
atitis patients, and mortality is high; however, mortality
is only 1%–3% among those without necrotizing pan-
creatitis.14,170,171  A report from the 1980s indicated a
mortality of 80% among patients with necrotizing pan-
creatitis,172 whereas ﬁgures from the 1990s have ranged
from 14% to 25% (Table 7). According to a Japanese
survey done in 1999,20 409 (33%) of the patients devel-
oped a severe disease. Contrast-enhanced CT scanning
was performed in 75% of these patients, and pancreatic
necrosis was observed in 42% of them. Based on these
ﬁndings, the incidence of pancreatic necrosis in Japan is
estimated to be 10%–15% (Level 3b). In this survey, the
mortality of severe acute pancreatitis with pancreatic
necrosis was 23%, whereas the mortality in severe acute
pancreatitis without pancreatic necrosis was 11%.
It has been suggested that the outcome of necrotizing
pancreatitis is associated with the extent of necrosis and
infectious complications (Level 4).169,178  Perez et al.
classiﬁed 99 patients with necrotizing pancreatitis into
two groups according to the extent of necrosis (<50% or
50%); they compared outcomes between the two
groups but found no signiﬁcant difference in the Acute
Physiology and Chronic Health Evaluation (APACHE)
II scores, the incidence of infected necrosis, MODS, or
organ failure. MODS and organ failure were strongly
associated with death. When organ failure accompanied
necrotizing pancreatitis, mortality increased to 47%;
mortality among the patients with MODS was 49%.170
According to reports from the United States and
Europe, infected pancreatic necrosis develops in 30%–
40% of patients with necrotizing pancreatitis.170 A 1999
survey done in Japan revealed that infected pancreatic
necrosis occurred in 152 (41%) of the 367 patients (42
patients with unconﬁrmed infection were excluded from
409 severe acute pancreatitis patients), and mortality
was 34% in infected pancreatic necrosis, as opposed
to only 7% in pancreatic necrosis without infection.
According to the report by Perez et al., the mortality in
infected necrosis was 19% (7/37), as opposed to only
11% (7/62) in sterile necrosis. Although the difference
in mortality between these groups was not statistically
signiﬁcant, the incidence of multiple organ failure,
which strongly affects the outcome, was much higher in
Table 7. Mortality from acute necrotizing pancreatitis
Acute
pancreatitis, all Severe acute Necrotizing acute
causes pancreatitis pancreatitis
Mortality Mortality Mortality
Author (year) n (%) n (%) n (%)
Karimgani et al.173 (1992) 26a 38
Bradley and Allen174 (1991) 194 38 15
Rattner et al.175 (1992) 73 25
Allardyce172 (1987) 348 5.2 43 33 17 80
Perez et al.170 (2002) 1110 99 14
Gullo et al.14 (2002) 1068 7.8 479 16
Lankisch et al.176 (2002) 326 7.1 64
Japan’s national survey177 (2000) 1240 7.4 409 22 117 23
aPatients with at least one systemic complication20 M. Sekimoto et al.: Epidemiology of acute pancreatitis
the infected necrosis patients than in the sterile necrosis
patients (41% vs. 23%, P = 0.07). It cannot be denied
that necrotizing pancreatitis is strongly linked to the
outcome.
Long-term outcome
About one-third to one-half of acute pancreatitis pa-
tients develop functional disorders of both the endo-
crine system and the exocrine system (diabetes mellitus
and fatty stool). However, many reports have shown
that most patients are in good general health at the time
of discharge and return to their usual daily routine
(Level 4).156,179,180 Although the age-standardized mor-
tality rate of patients who recovered from acute pancre-
atitis is higher than those without the disease, the
mortality was no different among patients over 65 years
of age (Level 4).143  Symptoms tend to decrease with
time among patients with fatty stool, whereas the symp-
toms of diabetes mellitus deteriorate (Level 1b).181 On
the other hand, some authors have emphasized that
endocrine function disorders after severe acute pancre-
atitis are associated with pancreatic resection (Level
2b),182 since insulin secretion is signiﬁcantly decreased
after pancreatic resection compared with conservative
treatments such as peritoneal lavage.
In 1999, a survey was done by the Japanese Ministry
of Health, Labour and Welfare that targeted 2098
patients who had experienced severe acute pancreatitis
in 1987.183 Information was gathered on 714 (34%) of
those patients. Some 15% had died, 22% had experi-
enced a recurrence, 24% had progressed to chronic
pancreatitis, and 13% had developed diabetes mellitus.
Some 80% of the respondents had been able to return
to their usual daily routine, i.e., the same routine that
they had enjoyed before the onset of the disease. The
most frequent cause of death was a malignant tumor
(36%). Forty-six percent of the patients who had a
recurrence experienced it within 1 year of the initial
attack.183
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